BRISTOL-MYERS Squibb has announced the TGA registration of its Opdivo (nivolumab) as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease - its ninth cancer indication.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 May 18